Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04686981
Other study ID # 20283-0-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2020
Est. completion date July 1, 2023

Study information

Verified date March 2024
Source Beijing Tsinghua Chang Gung Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Acute mesenteric artery thromboembolism(AMT) is one of the important causes of acute abdomen and intestinal necrosis. If the intestinal blood supply is not restore in time, the prognosis of the disease is often poor and even endangers the life of the patient. Through laparoscopic surgery combined with modern minimally invasive endovascular technology, the blood supply of patients' intestine is restored. Observe the perioperative vascular patency rate, all-cause mortality, and the probability of short bowel syndrome. Through the hybrid operating room, we want to seek a multidisciplinary collaborative treatment mode to improve the long-term survival rate of such patients with enough intestines and completely free from TPN, and improve the prognosis of these patients.


Description:

This study is a clinical cohort study; consecutively registered 30 patients with acute intestinal ischemia caused by superior mesenteric artery thromboembolism. If all the radiography, physical signs, and laboratory markers hint at intestinal necrosis, exploratory laparotomy followed by enterectomy and thrombectomy is the first choice. If none of them hint at intestinal necrosis, endovascular therapy is superior. Laparoscopic exploration followed by endovascular therapy was performed for other patients, after that the intestinal blood supply was evaluated again by laparoscopy. The main endpoints are the survival rate of bowel function preserved at 30 days, and the secondary endpoints are 30-day mortality, in-hospital mortality, symptoms-free survival rate, and rate of transition to laparotomy.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date July 1, 2023
Est. primary completion date June 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Patients with intestinal ischemia and acute abdomen pain caused by superior mesenteric artery thromboembolism Exclusion Criteria: - Those who have acute large-area myocardial infarction, large-area cerebral infarction, or have serious heart failure or sequelae of cerebral infarction within 1 month; - Combined with portal hypertension, gastrointestinal hemorrhage, portal and mesenteric venous reflux obstruction diseases; - Contrast agent allergy, severe renal insufficiency, and inability to perform intravascular surgery; - Past medical history contains superior mesenteric artery thromboembolism. - Patients diagnosed with intestinal necrosis and peritonitis before surgery based on physical signs and imaging studies who directly undergo laparotomy and incision for thrombectomy. - Patients without intestinal necrosis or peritonitis based on physical signs and imaging studies, who are treated by endovascular intervention therapy directly.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Beijing Tsinghua Chang Gung Hosipital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Tsinghua Chang Gung Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary survival rate with preserved bowel function Counting data within 30 days after operations
Secondary the incidence of all-cause mortality Counting data within 30 days after operations
Secondary vascular patency rate Counting data 180 days after operations
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Active, not recruiting NCT05563883 - Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
Terminated NCT02475187 - Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
Recruiting NCT00982514 - Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008 N/A
Completed NCT01420809 - Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection N/A
Terminated NCT00206089 - Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events Phase 3
Completed NCT00014352 - Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer Phase 2
Completed NCT00000614 - Prevention of Recurrent Venous Thromboembolism (PREVENT) Phase 3
Active, not recruiting NCT05656963 - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Completed NCT02935751 - Apixaban Discontinuation Prior to Major Surgery
Terminated NCT02579122 - REVIparin-BRIDging-in a General Practice Setting in GErmany
Completed NCT01696760 - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology N/A
Completed NCT00986154 - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Phase 3
Terminated NCT00662688 - Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer Phase 3
Completed NCT00260988 - A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery Phase 2/Phase 3
Terminated NCT00031837 - Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer Phase 3
Completed NCT03877770 - DVT After Cardiac Procedure
Completed NCT00024297 - Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters N/A
Recruiting NCT06118957 - Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery Phase 2